We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
The current YMAB market cap is 587.88M. The company's latest EPS is USD -0.4808 and P/E is -27.43.
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 20.75M | 20.45M | 23.36M | 19.93M | 22.8M |
| Operating Income | -7.22M | -7.75M | -7.68M | -6.91M | -9.79M |
| Net Income | -6.12M | -7.93M | -988k | -6.63M | -9.25M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 20.75M | 34.9M | 65.27M | 84.82M |
| Operating Income | -83M | -119.94M | -115.43M | -94.85M | -25.67M |
| Net Income | -81.03M | -119.34M | -55.28M | -95.61M | -21.43M |
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 132.4M | 128.88M | 127.87M | 123.32M | 144.04M |
| Total Liabilities | 27.72M | 28.73M | 26.88M | 24.13M | 48.7M |
| Total Equity | 104.68M | 100.15M | 100.99M | 99.19M | 95.34M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 216.37M | 132.05M | 212.78M | 141.46M | 127.87M |
| Total Liabilities | 17.46M | 26.21M | 32.68M | 32.24M | 26.88M |
| Total Equity | 198.9M | 105.84M | 180.11M | 109.22M | 100.99M |
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -17.86M | -19.2M | -27.23M | -3.48M | -3.18M |
| Investing | N/A | N/A | N/A | N/A | N/A |
| Financing | N/A | N/A | 100k | 588k | 2.35M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -73.5M | -91.23M | -102.56M | -75.92M | -27.23M |
| Investing | -1.97M | -2.79M | 61.04M | N/A | N/A |
| Financing | 134.7M | 2M | 108.31M | 84k | 100k |
| Market Cap | 587.88M |
| Price to Earnings Ratio | -27.43 |
| Price to Sales Ratio | 6.93 |
| Price to Cash Ratio | 7.48 |
| Price to Book Ratio | 5.82 |
| Dividend Yield | - |
| Shares Outstanding | 44.57M |
| Average Volume (1 week) | 365.92k |
| Average Volume (1 Month) | 213.12k |
| 52 Week Change | 167.00% |
| 52 Week High | 20.90 |
| 52 Week Low | 4.69 |
| Spread (Intraday) | 7.72 (58.62%) |
| Company Name | Y mAbs Therapeutics Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.ymabs.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
